JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Omentin-1 inhibits the development of benign prostatic hyperplasia by attenuating local inflammation

  • 0Department of Orthopedics, Movement System Injury and Repair Research Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Molecular Medicine +

|

March 23, 2024

|

March 23, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Intelectin-1 (ITLN-1) reduces inflammation and prostate enlargement in benign prostatic hyperplasia (BPH) models. This anti-inflammatory protein shows therapeutic potential for managing BPH by targeting local prostate inflammation.

Area Of Science

  • Urology
  • Inflammation Research
  • Molecular Biology

Background

  • Benign prostatic hyperplasia (BPH) is common in elderly men, with chronic inflammation a key factor.
  • Omentin-1, also known as intelectin-1 (ITLN-1), is an anti-inflammatory protein.
  • This study explores ITLN-1's role in mitigating BPH by modulating prostate inflammation.

Purpose Of The Study

  • To investigate the therapeutic potential of ITLN-1 in benign prostatic hyperplasia (BPH).
  • To determine if ITLN-1 can reduce inflammation associated with BPH development.

Main Methods

  • Utilized ITLN-1 knockout and adenovirus-mediated overexpression mouse models for in vivo studies.
  • Assessed BPH severity via prostate weight index and histological analyses.
  • Evaluated ITLN-1's effects on prostate epithelial cell proliferation and macrophage inflammatory response in vitro.

Main Results

  • ITLN-1 deficiency exacerbated BPH indicators, including increased prostate weight and TNF-α levels.
  • ITLN-1 overexpression reduced prostate weight, lumen area, and TNF-α in a BPH model.
  • ITLN-1 suppressed prostate epithelial cell proliferation and macrophage TNF-α production in vitro.

Conclusions

  • ITLN-1 significantly inhibits BPH development by reducing local prostate inflammation.
  • ITLN-1 demonstrates potential as a therapeutic target for managing benign prostatic hyperplasia.

Keywords:

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists 01:18

159

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists 01:23

173

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

The Tumor Microenvironment 02:17

6.6K

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Drugs that Stabilize Microtubules 01:15

2.0K

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Drugs that Destabilize Microtubules 01:10

2.0K

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...